CMBA
BBIO icon

C.M. Bidwell & Associates’s BridgeBio Pharma BBIO Stock Holding History

C.M. Bidwell & Associates’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,714
Closed -$202K – 504
2026
Q1 		$202K Buy
+2,714
New +$197K 0.09% 137

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

C.M. Bidwell & Associates's BBIO Position: Q2 2026 in Review

C.M. Bidwell & Associates sold out of BridgeBio Pharma (BBIO) in Q2 2026, closing a stake of 2,714 shares — an estimated $202K sold.

C.M. Bidwell & Associates first reported a position in BBIO in Q1 2026 and held it in 1 quarter. The position peaked at $202K in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • C.M. Bidwell & Associates reported no remaining BridgeBio Pharma position as of Q2 2026 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 2,714 BridgeBio Pharma shares in Q2 2026, an estimated $202K.
  • C.M. Bidwell & Associates first reported a position in BridgeBio Pharma in Q1 2026 and held it in 1 quarter.
  • C.M. Bidwell & Associates's BridgeBio Pharma position peaked at $202K in Q1 2026.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on C.M. Bidwell & Associates's 13F filing for Q2 2026, filed 11 Aug 2026.